Gender: All
Maximum age: N/A
Minimum age: 18 Years
Inclusion Criteria:
- Has histologically or cytologically confirmed melanoma.
- Has unresectable Stage III or Stage IV melanoma, as per American Joint Committee on
Cancer guidelines, not amenable to local therapy.
- Has been untreated for advanced or metastatic disease except as follows:
1. Proto-oncogene B-Raf (BRAF) V600 mutation-positive melanoma may have received
standard of care targeted therapy as first-line therapy for advanced or
metastatic disease. Participants that do not have a BRAF V600 mutation but did
receive BRAF or BRAF/MEKi therapy are eligible to participate in this study after
discussion with the medical monitor.
2. Prior adjuvant or neoadjuvant therapy, with targeted therapy or immunotherapy
(such as anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA-4],
anti-programmed cell death 1 [anti-PD-1] therapy or interferon) will only be
permitted if relapse did not occur during active treatment or within 6 months of
treatment discontinuation.
- Have documentation of BRAF V600-activating mutation status or consent to BRAF V600
mutation testing during the Screening period (participants with BRAF mutation-positive
melanoma as well as BRAF wild-type or unknown are eligible).
- Has an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
- Has the presence of =1 measurable lesion by computed tomography (CT) or magnetic
resonance imaging (MRI) per RECIST 1.1.
- Provides a tumor biopsy. Participants must submit tumor sample during Screening for
confirmation of adequacy of tumor tissue at a central pathology laboratory.
Participants who do not submit a tumor tissue sample will not be randomized. The tumor
biopsy may not be obtained from a lone target lesion. Confirmation of presence of
tumor tissue is not required prior to randomization.
- Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less
(except alopecia). If participant received major surgery or radiation therapy of >30
Gray (Gy), they must have recovered from the toxicity and/or complications from the
intervention.
- Male participants must agree to use contraception during the treatment period and for
at least 7 days after the last dose of study treatment and refrain from donating sperm
during this period. Please note that 7 days after lenvatinib/placebo is stopped, if
the participant is on pembrolizumab only, no male contraception measures are needed.
Contraception use by men should be consistent with local regulations regarding the
methods of contraception for those participating in clinical studies. If the
contraception requirements in the local label for any of the study interventions is
more stringent than the requirements above, the local label requirements are to be
followed.
- Female participants must not be pregnant, not breastfeeding, and =1 of the following
conditions applies:
1. Not a woman of childbearing potential (WOCBP). OR
2. A WOCBP who agrees to use study-approved contraception during the treatment
period and for at least 120 days after the last dose of study treatment.
- The participant (or legally acceptable representative) has provided documented
informed consent for the study.
- Has adequately controlled blood pressure (BP) with or without antihypertensive
medications, defined as BP =150/90 mmHg at screening and no change in antihypertensive
medications within 1 week before Cycle 1 Day 1.
- Has adequate organ function.
Exclusion Criteria:
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days before the first dose of study treatment.
- Has a known additional malignancy that is progressing or requires active treatment.
Exceptions include early stage cancers (carcinoma in situ or Stage 1, non-ulcerated
primary melanoma <1 mm in depth with no nodal involvement) treated with curative
intent, basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ
cervical cancer, or in situ breast cancer that has undergone potentially curative
therapy.
- Has known active central nervous system metastases and/or carcinomatous meningitis.
- Has ocular melanoma.
- Has known hypersensitivity to active substances or any of their excipients including
previous clinically significant hypersensitivity reaction to treatment with another
monoclonal antibody.
- Has an active autoimmune disease that has required systemic treatment in past 2 years
(i.e., with use of disease-modifying agents, corticosteroids or immunosuppressive
drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid
replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a
form of systemic treatment.
- Has an active infection requiring systemic therapy.
- Has known history of human immunodeficiency virus (HIV) infection
- Has known history of or is positive for hepatitis B virus or hepatitis C virus
infection.
- Has a history of (non-infectious) pneumonitis/interstitial lung disease that required
steroids or has current pneumonitis/interstitial lung disease.
- Has a history of active tuberculosis (Bacillus tuberculosis).
- Gastrointestinal malabsorption or any other condition that might affect the absorption
of lenvatinib.
- Has had a major surgery within 3 weeks prior to first dose of study intervention.
Note: Adequate wound healing after major surgery must be assessed clinically
independent of time elapsed for eligibility.
- Has a preexisting Grade =3 gastrointestinal or non-gastrointestinal fistula.
- Has radiographic evidence of encasement or invasion of major blood vessel, or of
intratumoral cavitation.
- Has active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior
to the first dose of study treatment.
- Has clinically significant cardiovascular disease from 12 months of the first dose of
study treatment including New York Heart Association Class III or IV congestive heart
failure, unstable angina, myocardial infarction, cerebral vascular accident, or
cardiac arrhythmia associated with hemodynamic instability.
- Has urine protein =1 g/24-hour. Note: Participants with =2+ (=100 mg/dL) proteinuria
on urine dipstick te
